Cell & Gene Therapy 2018
A new start-up has been launched with a dazzling, technology-enabled vision of putting genomics into the hands of the DNA’s owners – individuals – rather than what it calls genomics ‘middle men’.
Oxford Nanopore one of many firms cutting time and cost of sequencing
New study with 23andMe and Milken Institute looks to determine causes of depression.
AI can sift and analyse vast amounts of genomic data, enabling clinical scientists to better diagnose patients.
Service can now be marketed as test for Alheimer’s and Parkinson’s, among others.